Working With Patients To Use AI Against Rare Diseases

An Interview With Tim Guilliams, CEO of Healx

Tim Guilliams, CEO of Healx, talks about the company’s mission of creating from existing drugs new options for rare disease patients. The company is using artificial intelligence to find combination treatments against rare conditions, while working closely with patient groups as key partners in the development process. The goal: faster development timelines and cheaper therapies for patients.

Lightbulb_Hands
• Source: Shutterstock

Tim Guilliams, a 2020 In Vivo Rising Leader, co-founded UK-based Healx Ltd. in 2014 with a mission of developing affordable treatments for rare diseases. In October 2019, the artificial intelligence firm raised $56m in a Series B financing round, led by Atomico, one of Europe’s largest tech-focused venture capital firms. As CEO, Guilliams has grand plans for the future of Healx, as a tech-driven drug developer, not a service provider.

We started the company in 2014 with a few people around Cambridge University,” Guilliams told In Vivo in a recent...

More from C-Suite Speaks

More from Leadership